ANDRX To Acquire C Tex Pharmaceutical, Inc. From Shareholder Group.

Business Editors

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Nov. 17, 2000

ANDRX CORPORATION - ANDRX GROUP (Nasdaq:ADRX) announced today that it has entered into a definitive agreement to acquire C TEX Pharmaceuticals Inc., a privately owned pharmaceutical sales and marketing company based in Jackson, Mississippi. The acquisition is for $30 million, subject to adjustment, comprised of Andrx Group stock and cash, and will be accounted for using the purchase method of accounting. The acquisition is subject to various closing conditions. Andrx expects that the closing will occur within 45 days and that the acquisition will have a neutral to modestly accretive affect on its future financial results.

Andrx Co-Chairman and Chief Executive Officer, Alan P. Cohen, commented, "We are extremely pleased to add the 100-plus C Tex employees to the Andrx family and believe that this is an important step towards our goal of having a meaningful salesforce available when our first NDA brand product is launched."

Andrx is engaged in the formulation and commercialization of oral controlled-release pharmaceuticals utilizing its proprietary drug delivery technologies. In its ANDA program, Andrx is developing generic versions of selected high sales volume controlled-release brand name pharmaceuticals. In its NDA program, Andrx is developing its own brand name formulations of certain existing drugs that it believes may be improved by the application of Andrx Corporation's drug delivery technologies. Andrx also markets and distributes pharmaceutical products manufactured by third parties. Andrx Corporation's Cybear Group (Nasdaq: CYBA) intends to use the Internet to improve the efficiency of administrative and communications tasks of managing patient care - while addressing the healthcare industry's critical need for secure and reliable transmission of information.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risk and uncertainties. Andrx is a class of common stock of Andrx Corporation, therefore Andrx Corporation shareholders are subject to the risks and uncertainties described in Andrx Corporation's filings with the Securities and Exchange Commission, including Andrx Corporation's Annual Report on Form 10-K for the year ended December 31, 1999.